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Purpose: The objective of this report is to provide guidance in developing an appropriate analytical scope of 
testing for novel psychoactive substances (NPS) in the United States based on current trends and intelligence.     
This report is based on information available in Q1 2021 and is subject to change along with the drug market. 
Summary: The NPS landscape is changing rapidly, requiring laboratories to constantly remain abreast of new and 
emerging drugs locally, nationally, and internationally. To meet individualized needs, laboratories amend existing 
methods or develop new ones for detection and confirmation. This can be challenging for scientists as information 
about NPS detections can be regionalized and/or out-of-date, making it difficult to determine which drugs should 
be prioritized at a given time. NPS Discovery and the SOFT Designer Drugs Committee have established the 
below recommendations for NPS scope based on information from extensive collaborations, partnerships, and 
initiatives which yield national perspectives. Suggested cut-off concentrations or reporting limits (in ng/mL) are 
listed for each NPS. These values were categorized (i.e., <1, 1-10, and >10 ng/mL) and determined based on 
currently available quantitative data and/or comparison to structurally similar NPS within the given sub-class. 
Learn More About NPS Discovery: 
NPS Discovery at the CFSRE is working in collaboration with law enforcement, public 
health, and public safety agencies to rapidly identify emerging drugs associated with 
intoxications and adverse events. Our information, reports, and resources allow for the 
rapid dissemination of information to stakeholders and affected communities. For more 
information about our programs, visit our website or contact us via email. 
Website: www.npsdiscovery.org      Email: npsdiscovery@cfsre.org 
  
   
Recommended Scope for NPS Testing in the United States 
Based on Trends Observed in Q1 2021 
Benzodiazepines Opioids Stimulants & Hallucinogens Synthetic Cannabinoids 
TIER ONE (STRONGLY RECOMMEND) 
Etizolam† 1-10 Metonitazene <1 Eutylone >10 MDMB-4en-PINACA <1 
Clonazolam <1 o/m/p-Fluorofentanyl 1-10 3Cl-PCP / 4Cl-PCP <1 ADB-BINACA (-BUTINACA) <1 
8-Aminoclonazolam 1-10 Brorphine <1 3-HO-PCE / 4-HO-PCE  <1 4F-MDMB-BICA <1 
Flualprazolam 1-10 Isotonitazene <1 3-MeO-PCE / 4-MeO-PCE <1 5F-MDMB-PICA <1 
Flubromazolam 1-10 Carfentanil <1 * * * * 
TIER TWO (RECOMMEND) 
Bromazolam 1-10 AP-238 >10 2F-Deschloroketamine <1 5F-MDMB-PINACA (5F-ADB) <1 
Adinazolam† 1-10 2-Methyl AP-237 >10 3-MeO-PCP / 4-MeO-PCP <1 4F-MDMB-BINACA <1 
Pyrazolam 1-10 N-Pyrrolidino Etonitazene <1 3-HO-PCP / 4-HO-PCP <1 4F-ABINACA <1 
* * * * alpha-PHP / alpha-PiHP >10 * * 
TIER THREE (CONSIDER) 
Meclonazepam 1-10 Flunitazene 1-10 Deschloroketamine <1 ADB-4en-PINACA <1 
N-Desalkylflurazepam† 1-10 Butonitazene <1 N-Ethyl Deschloroketamine  <1 ACHMINACA <1 
Bromazepam† 1-10 o/m/p-Chlorofentanyl 1-10 3F-PCP / 4F-PCP <1 4CN-CUMYL-BINACA <1 
Deschloroetizolam 1-10 Dipyanone <1 Methylenedioxy-PV8 >10 5F-EDMB-PICA <1 
Note: This may not be an all-inclusive list. Laboratories should consider additional NPS for inclusion (or exclusion) based on local, national, and/or international trends. 
